Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Yichang HEC Changjiang Pharma / Equity Bottom-Up

<ul>
<li>HEC Pharma (1558 HK) launched multiple new products, which will reduce its over-dependence on a single drug. Among those, insulin and oral HCV drug have large market opportunities in China.</li>
<li>As of 30 June 2021, 11 products of the company have won the bid for centralized bulk purchase of drugs, including six products have won the bid in H1 2021.</li>
<li>HEC’s rich pipeline consists of 50 innovative class 1 drugs, targeting fast-growing therapeutic areas including oncology. Its late-stage pipeline will enable robust product launches in 2022 and beyond.</li>
</ul>


HEC Pharma (1558 HK) launched multiple new products, which will reduce its over-dependence on a single drug. Among those, insulin and oral HCV drug have large market opportunities in China.
As of 30 June 2021, 11 products of the company have won the bid for centralized bulk purchase of drugs, including six products have won the bid in H1 2021.
HEC’s rich pipeline consists of 50 innovative class 1 drugs, targeting fast-growing therapeutic areas including oncology. Its late-stage pipeline will enable robust product launches in 2022 and beyond.


Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

China Huarong Asset Management / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/china-huarong-asset-management" target="_blank" data-smartkarma-citation="entities:968:1" rel="noopener">China Huarong Asset Management (2799 HK)</a>, which is expected to be in contravention of Hong Kong's public float, is contemplating the "full circulation" of some domestic shares. </li>
<li>If implemented, the conversion of these domestic shares would be largely ceremonial.</li>
<li>To date, 28 companies have sought approval to convert their domestic shares and/or unlisted foreign shares into H shares on the Hong Kong exchange. </li>
</ul>



China Huarong Asset Management (2799 HK), which is expected to be in contravention of Hong Kong's public float, is contemplating the "full circulation" of some domestic shares. 
If implemented, the conversion of these domestic shares would be largely ceremonial.
To date, 28 companies have sought approval to convert their domestic shares and/or unlisted foreign shares into H shares on the Hong Kong exchange. 


China Huarong (2799 HK)'s Full Circulation

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai Ark Biopharmaceutical / Equity Capital Markets

In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29th, 2021, <a href="https://www.smartkarma.com/entities/shanghai-ark-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:33766:1" rel="noopener">Shanghai Ark Biopharmaceutical (SAB HK)</a> submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.

In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29th, 2021, Shanghai Ark Biopharmaceutical (SAB HK) submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

On February 24, 2021, <a href="https://www.smartkarma.com/entities/apollomics-inc" target="_blank" data-smartkarma-citation="entities:32186:1" rel="noopener">Apollomics Inc (1435488D US)</a> applied to be listed on the main board of the Hong Kong Stock Exchange. The Company is an innovative biotechnology company focusing on the discovery and development of oncology therapies. Apollomics intends to use the proceeds of this fundraising for R&amp;D activities, preparation for registration filings, commercial process development, manufacturing registrational trial material, expansion of business and other general corporate purposes. The following mainly provided insights on its major products in the pipeline.

On February 24, 2021, Apollomics Inc (1435488D US) applied to be listed on the main board of the Hong Kong Stock Exchange. The Company is an innovative biotechnology company focusing on the discovery and development of oncology therapies. Apollomics intends to use the proceeds of this fundraising for R&amp;D activities, preparation for registration filings, commercial process development, manufacturing registrational trial material, expansion of business and other general corporate purposes. The following mainly provided insights on its major products in the pipeline.

Pre-IPO Apollomics - Concerns on Competition and Commercialization Despite Some Promising Products

<div>
This update is the latest in a series dating back to <a href="https://skr.ma/c7hcH" target="_blank" rel="noopener">Legend's Conversion of Domestic Shares</a> in June 2018.
To date, 20 companies have sought approval to convert their domestic shares into H shares, which would then be eligible to be listed and traded on Hong Kong's stock exchange.
13 companies have now been given CSRC and Hong Kong listing approval to convert such shares. Only two of those have seen any noticeable movement in the converted shares.
In the past four months, two companies have withdrawn their application to convert their domestic shares, citing further improvement in the rules and regulations of the domestic capital market, among other factors.  
</div>
<div>
As always, more below the fold. 
</div>


This update is the latest in a series dating back to Legend's Conversion of Domestic Shares in June 2018.
To date, 20 companies have sought approval to convert their domestic shares into H shares, which would then be eligible to be listed and traded on Hong Kong's stock exchange.
13 companies have now been given CSRC and Hong Kong listing approval to convert such shares. Only two of those have seen any noticeable movement in the converted shares.
In the past four months, two companies have withdrawn their application to convert their domestic shares, citing further improvement in the rules and regulations of the domestic capital market, among other factors.  


As always, more below the fold. 


Full Circulation Of H-Shares: January 2021 Update

Hong Kong

YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs.  The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yichang HEC Changjiang Pharma (1558 HK)